Yujie Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yujie Li has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Wenbo Wang
Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Jinan, 250001, People's Republic of China
11 shared publications Jiayi Zhang
Shandong University of Traditional Chinese Medicine Jinan China
9 shared publicationsXin Wang
Shandong University of Traditional Chinese Medicine Jinan China
7 shared publicationsYufeng Zhang
Shandong University of Traditional Chinese Medicine Jinan China
7 shared publicationsFengyi Zhang
Shandong University of Traditional Chinese Medicine First Clinical Medical College, Jinan, People’s Republic of China
6 shared publicationsYaxin Chen
Shandong University of Traditional Chinese Medicine Jinan China
6 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in Phytotherapy Research
Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage
Metabolic dysfunction–associated fatty liver disease (MAFLD) is associated with hepatic lipid accumulation, inflammation, and hepatocyte apoptosis. Astragaloside IV (AS‐IV) has been reported to regulate lipid metabolism, but its effects on hepatocyte apoptosis in MAFLD remain unclear. We investigated the effects of AS‐IV in db/db mice and free fatty acid (FFA)–treated HepG2 cells using biochemical assays, histological staining, measurements of inflammatory markers and reactive oxygen species, and apoptosis assays. Network pharmacology and molecular docking were used to identify candidate targets, followed by analyses of CASP3 and PARP1 expression and cleavage and CASP3 overexpression experiments. AS‐IV reduced hepatic and cellular triglyceride accumulation, inflammatory markers, and hepatocyte apoptosis, and improved liver histology and serum markers of liver injury in db/db mice. These effects were accompanied by reduced CASP3 activation and PARP1 cleavage. In HepG2 cells, AS‐IV also attenuated the changes associated with CASP3 overexpression. Together, these findings suggest that suppression of CASP3‐associated PARP1 cleavage may contribute to the protective effects of AS‐IV in these experimental models of MAFLD.
- 13 November 2026
- Published by Wiley in Phytotherapy Research
Open AccessAstragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage
Metabolic dysfunction–associated fatty liver disease (MAFLD) is associated with hepatic lipid accumulation, inflammation, and hepatocyte apoptosis. Astragaloside IV (AS‐IV) has been reported to regulate lipid metabolism, but its effects on hepatocyte apoptosis in MAFLD remain unclear. We investigated the effects of AS‐IV in db/db mice and free fatty acid (FFA)–treated HepG2 cells using biochemical assays, histological staining, measurements of inflammatory markers and reactive oxygen species, and apoptosis assays. Network pharmacology and molecular docking were used to identify candidate targets, followed by analyses of CASP3 and PARP1 expression and cleavage and CASP3 overexpression experiments. AS‐IV reduced hepatic and cellular triglyceride accumulation, inflammatory markers, and hepatocyte apoptosis, and improved liver histology and serum markers of liver injury in db/db mice. These effects were accompanied by reduced CASP3 activation and PARP1 cleavage. In HepG2 cells, AS‐IV also attenuated the changes associated with CASP3 overexpression. Together, these findings suggest that suppression of CASP3‐associated PARP1 cleavage may contribute to the protective effects of AS‐IV in these experimental models of MAFLD.
- Open Access
- 29 September 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 225
Berberine attenuates diabetic kidney injury via FOXO1/SP1-associated regulation of renal SGLT-2 expression
Background: Berberine (BBR), a plant-derived isoquinoline alkaloid, has been reported to exert anti-hyperglycemic and renoprotective effects. However, the mechanism by which BBR regulates renal glucose transport under diabetic conditions remains unclear. Sodium-glucose cotransporter-2 (SGLT-2), mainly expressed in renal proximal tubular epithelial cells, plays a key role in renal glucose reabsorption. This study investigated whether BBR attenuates diabetic kidney injury by regulating SGLT-2 expression and examined the potential involvement of FOXO1 and SP1 in this regulation. Methods: Db/db mice and high-glucose-exposed human kidney-2 (HK-2) cells were used to evaluate the effects of BBR, empagliflozin (EM), and their combination. Metabolic and renal phenotypes were assessed by biochemical, histological, and ultrastructural analyses. Network pharmacology, public transcriptomic data mining, molecular docking, cellular thermal shift assay (CETSA), quantitative real-time PCR, western blotting, immunofluorescence, nuclear-cytoplasmic fractionation, co-immunoprecipitation, 2-NBDG uptake, dual-luciferase reporter assays, FOXO1 overexpression, and pharmacological interference with SP1-associated regulation were performed to investigate the regulatory mechanism. Results: Both BBR and EM improved metabolic abnormalities and renal injury in db/db mice, whereas combined treatment produced marked metabolic and renal improvements but was accompanied by an increasing trend in AST. BBR reduced hyperglycemia, improved glucose tolerance and enhanced the glucose-lowering response to exogenous insulin during the ITT, suppressed urinary albumin excretion, and alleviated renal histopathological and ultrastructural damage. Molecular docking and qualitative CETSA findings suggested that FOXO1 may represent a potential molecular target of BBR. In HK-2 cells, high-glucose stimulation increased SGLT-2 expression and glucose uptake, accompanied by dysregulation of FOXO1 and SP1 signaling. BBR downregulated FOXO1 and SGLT-2, restored SP1 and phosphorylated FOXO1 levels, and reduced glucose uptake under high-glucose conditions. FOXO1 overexpression attenuated the BBR-induced reduction in SGLT-2 expression, whereas pharmacological interference with SP1-associated regulation further supported the functional involvement of SP1 in SGLT-2 regulation. Conclusion: BBR attenuates diabetic kidney injury, at least in part, through FOXO1/SP1-associated regulation of renal SGLT-2 expression. These findings support the involvement of a FOXO1/SP1-associated regulatory axis in renal tubular glucose handling under diabetic conditions.
- 29 September 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 225
Open AccessBerberine attenuates diabetic kidney injury via FOXO1/SP1-associated regulation of renal SGLT-2 expression
Background: Berberine (BBR), a plant-derived isoquinoline alkaloid, has been reported to exert anti-hyperglycemic and renoprotective effects. However, the mechanism by which BBR regulates renal glucose transport under diabetic conditions remains unclear. Sodium-glucose cotransporter-2 (SGLT-2), mainly expressed in renal proximal tubular epithelial cells, plays a key role in renal glucose reabsorption. This study investigated whether BBR attenuates diabetic kidney injury by regulating SGLT-2 expression and examined the potential involvement of FOXO1 and SP1 in this regulation. Methods: Db/db mice and high-glucose-exposed human kidney-2 (HK-2) cells were used to evaluate the effects of BBR, empagliflozin (EM), and their combination. Metabolic and renal phenotypes were assessed by biochemical, histological, and ultrastructural analyses. Network pharmacology, public transcriptomic data mining, molecular docking, cellular thermal shift assay (CETSA), quantitative real-time PCR, western blotting, immunofluorescence, nuclear-cytoplasmic fractionation, co-immunoprecipitation, 2-NBDG uptake, dual-luciferase reporter assays, FOXO1 overexpression, and pharmacological interference with SP1-associated regulation were performed to investigate the regulatory mechanism. Results: Both BBR and EM improved metabolic abnormalities and renal injury in db/db mice, whereas combined treatment produced marked metabolic and renal improvements but was accompanied by an increasing trend in AST. BBR reduced hyperglycemia, improved glucose tolerance and enhanced the glucose-lowering response to exogenous insulin during the ITT, suppressed urinary albumin excretion, and alleviated renal histopathological and ultrastructural damage. Molecular docking and qualitative CETSA findings suggested that FOXO1 may represent a potential molecular target of BBR. In HK-2 cells, high-glucose stimulation increased SGLT-2 expression and glucose uptake, accompanied by dysregulation of FOXO1 and SP1 signaling. BBR downregulated FOXO1 and SGLT-2, restored SP1 and phosphorylated FOXO1 levels, and reduced glucose uptake under high-glucose conditions. FOXO1 overexpression attenuated the BBR-induced reduction in SGLT-2 expression, whereas pharmacological interference with SP1-associated regulation further supported the functional involvement of SP1 in SGLT-2 regulation. Conclusion: BBR attenuates diabetic kidney injury, at least in part, through FOXO1/SP1-associated regulation of renal SGLT-2 expression. These findings support the involvement of a FOXO1/SP1-associated regulatory axis in renal tubular glucose handling under diabetic conditions.
- Open Access
- 18 October 2025
- Published by Elsevier in Experimental Gerontology
- Vol. 211, 112935
SGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: A Mendelian randomization study
- 18 October 2025
- Published by Elsevier in Experimental Gerontology
- Vol. 211, 112935
Open AccessSGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: A Mendelian randomization study
- Open Access
- 17 October 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (10) , e70159
Diabetic Kidney Disease‐Associated Pathological Angiogenesis: The Role of Aquaporin‐1
Diabetic kidney disease (DKD) is recognized as one of the leading causes of chronic kidney disease (CKD) and end‐stage kidney disease (ESKD) worldwide, representing a rapidly growing global public health concern. Despite significant advances in understanding the complex pathophysiological mechanisms of DKD, curative treatments are currently unavailable, and the reversal of established renal injury remains an elusive goal in clinical practice. Among various pathological features, aberrant angiogenesis has been closely associated with glomerular injury and the early development of proteinuria in DKD, playing a crucial role in driving disease progression. However, the molecular mechanisms underlying this pathological angiogenesis in DKD remain incompletely understood and warrant further elucidation. Recent research has increasingly implicated aquaporins (AQPs), a family of transmembrane water channel proteins, in the pathogenesis of both acute and chronic kidney disorders, including DKD. In particular, aquaporin‐1 (AQP1), which is highly expressed in renal tissues, has emerged as a potential modulator of angiogenic activity within the kidney microenvironment. Although AQP1 and aberrant angiogenesis have been individually explored in the context of DKD, no comprehensive review has systematically examined their interrelationship. This review consolidates current evidence regarding the role of AQP1 in pathological angiogenesis during DKD progression, highlighting its potential significance and identifying gaps that warrant further investigation.
- 17 October 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (10) , e70159
Open AccessDiabetic Kidney Disease‐Associated Pathological Angiogenesis: The Role of Aquaporin‐1
Diabetic kidney disease (DKD) is recognized as one of the leading causes of chronic kidney disease (CKD) and end‐stage kidney disease (ESKD) worldwide, representing a rapidly growing global public health concern. Despite significant advances in understanding the complex pathophysiological mechanisms of DKD, curative treatments are currently unavailable, and the reversal of established renal injury remains an elusive goal in clinical practice. Among various pathological features, aberrant angiogenesis has been closely associated with glomerular injury and the early development of proteinuria in DKD, playing a crucial role in driving disease progression. However, the molecular mechanisms underlying this pathological angiogenesis in DKD remain incompletely understood and warrant further elucidation. Recent research has increasingly implicated aquaporins (AQPs), a family of transmembrane water channel proteins, in the pathogenesis of both acute and chronic kidney disorders, including DKD. In particular, aquaporin‐1 (AQP1), which is highly expressed in renal tissues, has emerged as a potential modulator of angiogenic activity within the kidney microenvironment. Although AQP1 and aberrant angiogenesis have been individually explored in the context of DKD, no comprehensive review has systematically examined their interrelationship. This review consolidates current evidence regarding the role of AQP1 in pathological angiogenesis during DKD progression, highlighting its potential significance and identifying gaps that warrant further investigation.
- 30 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 354, 120514
Pilose antler peptide enhances diabetic fracture healing by modulating the CREB-Smad2/3-Runx2 signaling axis
- 30 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 354, 120514
Pilose antler peptide enhances diabetic fracture healing by modulating the CREB-Smad2/3-Runx2 signaling axis
- Open Access
- 27 September 2024
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 23 (1) , 1-12
Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease in patients with diabetes in the United States: a cross-sectional study
This paper investigated the link between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease (DKD) in adult diabetic patients and identified the optimal NHHR value for impacting DKD. This cross-sectional research made use of records from the National Health and Nutrition Examination Survey (NHANES) executed between 2005 and 2016. The link of NHHR to DKD risk was analyzed by logistic regression and restricted cubic spline (RCS) models. The stability and reliability of the results were assessed by subgroup analysis and sensitivity analysis. In total, 4,177 participants were involved. As a continuous variable, NHHR was markedly connected to an increased risk of DKD (OR 1.07, 95% CI 1.02, 1.12, P < 0.01). When NHHR was grouped in quartiles, relative to the reference set, the highest NHHR group was also linked to a heightened risk of DKD (OR 1.23, 95% CI 1.01, 1.50, P < 0.05). The outcome of RCS show a “J” shaped correlation between NHHR and DKD risk (P for nonlinear = 0.0136). The risk of developing DKD was the lowest when NHHR equals 2.66. Subgroup analysis revealed that the link of NHHR to DKD persisted in participants aged below 40, females, non-smokers, and those without hyperuricemia. Sensitivity analysis demonstrated a certain robustness in this association. A meaningful link is present between NHHR and DKD. An NHHR value of around 2.66 could represent the ideal cutoff for assessing DKD risk.
- 27 September 2024
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 23 (1) , 1-12
Open AccessAssociation between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease in patients with diabetes in the United States: a cross-sectional study
This paper investigated the link between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease (DKD) in adult diabetic patients and identified the optimal NHHR value for impacting DKD. This cross-sectional research made use of records from the National Health and Nutrition Examination Survey (NHANES) executed between 2005 and 2016. The link of NHHR to DKD risk was analyzed by logistic regression and restricted cubic spline (RCS) models. The stability and reliability of the results were assessed by subgroup analysis and sensitivity analysis. In total, 4,177 participants were involved. As a continuous variable, NHHR was markedly connected to an increased risk of DKD (OR 1.07, 95% CI 1.02, 1.12, P < 0.01). When NHHR was grouped in quartiles, relative to the reference set, the highest NHHR group was also linked to a heightened risk of DKD (OR 1.23, 95% CI 1.01, 1.50, P < 0.05). The outcome of RCS show a “J” shaped correlation between NHHR and DKD risk (P for nonlinear = 0.0136). The risk of developing DKD was the lowest when NHHR equals 2.66. Subgroup analysis revealed that the link of NHHR to DKD persisted in participants aged below 40, females, non-smokers, and those without hyperuricemia. Sensitivity analysis demonstrated a certain robustness in this association. A meaningful link is present between NHHR and DKD. An NHHR value of around 2.66 could represent the ideal cutoff for assessing DKD risk.
- Open Access
- 14 September 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-13
A causal relationship between bone mineral density and breast cancer risk: a mendelian randomization study based on east Asian population
Breast cancer (BC) poses significant burdens on women globally. While past research suggests a potential link between bone mineral density (BMD) and BC risk, findings remain inconsistent. Our study aims to elucidate the causal relationship between BMD and BC in East Asians using bidirectional Mendelian randomization (MR). Genetic association data for bone mineral density T-scores (BMD-T) and Z-scores (BMD-Z) (Sample size = 92,615) and BC from two different sources (Sample size1 = 98,283; Sample size2 = 79,550) were collected from publicly available genome-wide association studies (GWAS). Single-nucleotide polymorphisms (SNPs) associated with BMD-T and BMD-Z as phenotype-related instrumental variables (IVs) were used, with BC as the outcome. As the primary means of causal inference, the inverse variance weighted (IVW) approach was employed. Heterogeneity analysis was conducted using Cochran’s Q test, while MR-Egger regression analysis was implemented to assess the pleiotropic effects of the IVs. Sensitivity analyses were performed using methods such as MR-Egger, weighted median, and weighted mode to analyze the robustness and reliability of the results. The MR-PRESSO method and the RadialMR were used to detect and remove outliers. The PhenoScanner V2 website was utilized to exclude confounding factors shared between BMD and BC. Besides, the Bonferroni correction was also used to adjust the significance threshold. Then, the meta-analysis method was applied to combine the MR analysis results from the two BC sources. Finally, a reverse MR analysis was conducted. The results of the IVW method were consolidated through meta-analysis, revealing a positive correlation between genetically predicted BMD-T ( $$\:OR\:=\:1.22$$ , $$\:95\%\:CI:\:1.13-1.33$$ , $$\:P<0.001$$ ) and BMD-Z ( $$\:OR\:=\:1.17$$ , $$\:\:95\%\:CI:\:1.09-1.26$$ , $$\:P<0.001$$ ) with increased BC risk. The Cochran’s $$\:Q$$ test and MR-Egger regression suggested that neither of these causal relationships was affected by heterogeneity or horizontal pleiotropy. The sensitivity analyses supported the IVW results, indicating the robustness of the findings. Reverse MR analysis showed no causal relationship between BC and BMD. Our MR study results provide evidence for the causal relationship between BMD and BC risk in East Asian populations, suggesting that BMD screening is of great significance in detecting and preventing BC.- 14 September 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-13
Open AccessA causal relationship between bone mineral density and breast cancer risk: a mendelian randomization study based on east Asian population
Breast cancer (BC) poses significant burdens on women globally. While past research suggests a potential link between bone mineral density (BMD) and BC risk, findings remain inconsistent. Our study aims to elucidate the causal relationship between BMD and BC in East Asians using bidirectional Mendelian randomization (MR). Genetic association data for bone mineral density T-scores (BMD-T) and Z-scores (BMD-Z) (Sample size = 92,615) and BC from two different sources (Sample size1 = 98,283; Sample size2 = 79,550) were collected from publicly available genome-wide association studies (GWAS). Single-nucleotide polymorphisms (SNPs) associated with BMD-T and BMD-Z as phenotype-related instrumental variables (IVs) were used, with BC as the outcome. As the primary means of causal inference, the inverse variance weighted (IVW) approach was employed. Heterogeneity analysis was conducted using Cochran’s Q test, while MR-Egger regression analysis was implemented to assess the pleiotropic effects of the IVs. Sensitivity analyses were performed using methods such as MR-Egger, weighted median, and weighted mode to analyze the robustness and reliability of the results. The MR-PRESSO method and the RadialMR were used to detect and remove outliers. The PhenoScanner V2 website was utilized to exclude confounding factors shared between BMD and BC. Besides, the Bonferroni correction was also used to adjust the significance threshold. Then, the meta-analysis method was applied to combine the MR analysis results from the two BC sources. Finally, a reverse MR analysis was conducted. The results of the IVW method were consolidated through meta-analysis, revealing a positive correlation between genetically predicted BMD-T ( $$\:OR\:=\:1.22$$ , $$\:95\%\:CI:\:1.13-1.33$$ , $$\:P<0.001$$ ) and BMD-Z ( $$\:OR\:=\:1.17$$ , $$\:\:95\%\:CI:\:1.09-1.26$$ , $$\:P<0.001$$ ) with increased BC risk. The Cochran’s $$\:Q$$ test and MR-Egger regression suggested that neither of these causal relationships was affected by heterogeneity or horizontal pleiotropy. The sensitivity analyses supported the IVW results, indicating the robustness of the findings. Reverse MR analysis showed no causal relationship between BC and BMD. Our MR study results provide evidence for the causal relationship between BMD and BC risk in East Asian populations, suggesting that BMD screening is of great significance in detecting and preventing BC. - Open Access
- 8 February 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (2) , e0298070
Small dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization
Background: Patients with T2DM often suffer from CVD-related complications, significantly impacting morbidity and mortality rates. The upsurge in CVD prevalence among them is partly linked to sd LDL particles. Understanding the mechanisms behind elevated sd LDL levels is critical for preventing and managing cardiovascular complications in diabetes. Methods: MR was employed to identify instrumental variables and establish causality, exploring underlying mechanisms. Results: Notably, T2DM itself, insulin resistance, and fasting glucose seemingly do not directly impact sd LDL levels. Instead, the presence of T2DM or insulin resistance, leading to reduced HDL cholesterol or elevated TG levels, directly contributes to subsequent sd LDL increases, indicating a comprehensive mediating effect. While LDL cholesterol levels correlate positively with sd LDL, they appear unaffected by T2DM or insulin resistance. Importantly, hypertension induced by T2DM or insulin resistance exhibits a positive effect on sd LDL reversal. Unlike T2DM or insulin resistance, blood glucose levels show no significant impact on all processes. Conclusions: It is hoped that these insights might influence the treatment of patients with diabetes and the management of blood parameters in clinical practice. Examining the effect of T2DM or insulin resistance on sd LDL within HDL cholesterol and triglycerides pathways might provide valuable insights for targeted cardiovascular treatments. Additionally, the study’s exploration of the potential positive effects of elevated blood pressure on sd LDL reversal may introduce novel considerations for blood pressure management in patients with diabetes.
- 8 February 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (2) , e0298070
Open AccessSmall dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization
Background: Patients with T2DM often suffer from CVD-related complications, significantly impacting morbidity and mortality rates. The upsurge in CVD prevalence among them is partly linked to sd LDL particles. Understanding the mechanisms behind elevated sd LDL levels is critical for preventing and managing cardiovascular complications in diabetes. Methods: MR was employed to identify instrumental variables and establish causality, exploring underlying mechanisms. Results: Notably, T2DM itself, insulin resistance, and fasting glucose seemingly do not directly impact sd LDL levels. Instead, the presence of T2DM or insulin resistance, leading to reduced HDL cholesterol or elevated TG levels, directly contributes to subsequent sd LDL increases, indicating a comprehensive mediating effect. While LDL cholesterol levels correlate positively with sd LDL, they appear unaffected by T2DM or insulin resistance. Importantly, hypertension induced by T2DM or insulin resistance exhibits a positive effect on sd LDL reversal. Unlike T2DM or insulin resistance, blood glucose levels show no significant impact on all processes. Conclusions: It is hoped that these insights might influence the treatment of patients with diabetes and the management of blood parameters in clinical practice. Examining the effect of T2DM or insulin resistance on sd LDL within HDL cholesterol and triglycerides pathways might provide valuable insights for targeted cardiovascular treatments. Additionally, the study’s exploration of the potential positive effects of elevated blood pressure on sd LDL reversal may introduce novel considerations for blood pressure management in patients with diabetes.
- Open Access
- 26 October 2023
- Published by Springer Nature in Molecular Medicine
- Vol. 29 (1) , 1-12
CRTC2 activates the epithelial–mesenchymal transition of diabetic kidney disease through the CREB-Smad2/3 pathway
Background: Epithelial–mesenchymal transition (EMT) plays a key role in tubulointerstitial fibrosis, which is a hallmark of diabetic kidney disease (DKD). Our previous studies showed that CRTC2 can simultaneously regulate glucose metabolism and lipid metabolism. However, it is still unclear whether CRTC2 participates in the EMT process in DKD. Methods: We used protein‒protein network (PPI) analysis to identify genes that were differentially expressed during DKD and EMT. Then, we constructed a diabetic mouse model by administering STZ plus a high-fat diet, and we used HK-2 cells that were verified to confirm the bioinformatics research results. The effects that were exerted by CRTC2 on epithelial-mesenchymal transition in diabetic kidney disease through the CREB-Smad2/3 signaling pathway were investigated in vivo and in vitro by real-time PCR, WB, IHC and double luciferase reporter gene experiments. Results: First, bioinformatics research showed that CRTC2 may promote EMT in diabetic renal tubules through the CREB-Smad2/3 signaling pathway. Furthermore, the Western blotting and real-time PCR results showed that CRTC2 overexpression reduced the expression of E-cadherin in HK-2 cells. The CRTC2 and α-SMA levels were increased in STZ-treated mouse kidneys, and the E-cadherin level was reduced. The luciferase activity of α-SMA, which is the key protein in EMT, was sharply increased in response to the overexpression of CRTC2 and decreased after the silencing of CREB and Smad2/3. However, the expression of E-cadherin showed the opposite trends. In the real-time PCR experiment, the mRNA expression of α-SMA increased significantly when CRTC2 was overexpressed but partially decreased when CREB and Smad2/3 were silenced. However, E-cadherin expression showed the opposite result. Conclusion: This study demonstrated that CRTC2 activates the EMT process via the CREB-Smad2/3 signaling pathway in diabetic renal tubules.
- 26 October 2023
- Published by Springer Nature in Molecular Medicine
- Vol. 29 (1) , 1-12
Open AccessCRTC2 activates the epithelial–mesenchymal transition of diabetic kidney disease through the CREB-Smad2/3 pathway
Background: Epithelial–mesenchymal transition (EMT) plays a key role in tubulointerstitial fibrosis, which is a hallmark of diabetic kidney disease (DKD). Our previous studies showed that CRTC2 can simultaneously regulate glucose metabolism and lipid metabolism. However, it is still unclear whether CRTC2 participates in the EMT process in DKD. Methods: We used protein‒protein network (PPI) analysis to identify genes that were differentially expressed during DKD and EMT. Then, we constructed a diabetic mouse model by administering STZ plus a high-fat diet, and we used HK-2 cells that were verified to confirm the bioinformatics research results. The effects that were exerted by CRTC2 on epithelial-mesenchymal transition in diabetic kidney disease through the CREB-Smad2/3 signaling pathway were investigated in vivo and in vitro by real-time PCR, WB, IHC and double luciferase reporter gene experiments. Results: First, bioinformatics research showed that CRTC2 may promote EMT in diabetic renal tubules through the CREB-Smad2/3 signaling pathway. Furthermore, the Western blotting and real-time PCR results showed that CRTC2 overexpression reduced the expression of E-cadherin in HK-2 cells. The CRTC2 and α-SMA levels were increased in STZ-treated mouse kidneys, and the E-cadherin level was reduced. The luciferase activity of α-SMA, which is the key protein in EMT, was sharply increased in response to the overexpression of CRTC2 and decreased after the silencing of CREB and Smad2/3. However, the expression of E-cadherin showed the opposite trends. In the real-time PCR experiment, the mRNA expression of α-SMA increased significantly when CRTC2 was overexpressed but partially decreased when CREB and Smad2/3 were silenced. However, E-cadherin expression showed the opposite result. Conclusion: This study demonstrated that CRTC2 activates the EMT process via the CREB-Smad2/3 signaling pathway in diabetic renal tubules.
- 11 September 2023
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (12) , 2013-2025
Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
This meta-analysis aims to evaluate the impact of Sodium Glucose Transporter 2 (SGLT2) inhibitors on fractures, bone mineral density (BMD), and bone metabolism markers in type 2 diabetes mellitus (T2DM) patients. Pooled relative risk (RR) with 95% confidence interval (CI) assessed the relationship between SGLT2 inhibitors and fracture risk. Weighted mean difference (WMD) with 95% CI explored the correlation between SGLT2 inhibitors and BMD, as well as bone metabolism markers. A total of 20 randomised controlled trials (RCTs) involving 12,764 patients were analysed. No significant association emerged between SGLT2 inhibitor use and elevated fracture risk (pooled RR = 1.21, 95% CI [0.95, 1.54], I2 = 22%). Furthermore, SGLT2 inhibitors exhibited no substantial effects on BMD changes at the lumbar spine (WMD = -0.02, 95% CI [-0.38, 0.34]), femoral neck (WMD = 0.11, 95% CI [-0.28, 0.50]), total hip (WMD = -0.20, 95% CI [-0.41, 0.01]), and distal forearm (WMD = -0.20, 95% CI [-0.62, 0.22]). Similarly, no notable impact of SGLT2 inhibitors on bone metabolism markers, including CTX (WMD = 0.04, 95% CI [-0.02, 0.09]), P1NP (WMD = 1.06, 95% CI [-0.44, 2.57]), PTH (WMD = 0.34, 95% CI [-0.07, 0.75]), calcium (WMD = 0.01, 95% CI [-0.02, 0.04]), and phosphate (WMD = 2.37, 95% CI [-0.76, 5.49]). The findings suggest that the utilization of SGLT2 inhibitors is not significantly linked to an elevated risk of fractures in individuals with T2DM. However, further clinical investigations and extended follow-up periods are warranted to establish more conclusive determinations.
- 11 September 2023
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (12) , 2013-2025
Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
This meta-analysis aims to evaluate the impact of Sodium Glucose Transporter 2 (SGLT2) inhibitors on fractures, bone mineral density (BMD), and bone metabolism markers in type 2 diabetes mellitus (T2DM) patients. Pooled relative risk (RR) with 95% confidence interval (CI) assessed the relationship between SGLT2 inhibitors and fracture risk. Weighted mean difference (WMD) with 95% CI explored the correlation between SGLT2 inhibitors and BMD, as well as bone metabolism markers. A total of 20 randomised controlled trials (RCTs) involving 12,764 patients were analysed. No significant association emerged between SGLT2 inhibitor use and elevated fracture risk (pooled RR = 1.21, 95% CI [0.95, 1.54], I2 = 22%). Furthermore, SGLT2 inhibitors exhibited no substantial effects on BMD changes at the lumbar spine (WMD = -0.02, 95% CI [-0.38, 0.34]), femoral neck (WMD = 0.11, 95% CI [-0.28, 0.50]), total hip (WMD = -0.20, 95% CI [-0.41, 0.01]), and distal forearm (WMD = -0.20, 95% CI [-0.62, 0.22]). Similarly, no notable impact of SGLT2 inhibitors on bone metabolism markers, including CTX (WMD = 0.04, 95% CI [-0.02, 0.09]), P1NP (WMD = 1.06, 95% CI [-0.44, 2.57]), PTH (WMD = 0.34, 95% CI [-0.07, 0.75]), calcium (WMD = 0.01, 95% CI [-0.02, 0.04]), and phosphate (WMD = 2.37, 95% CI [-0.76, 5.49]). The findings suggest that the utilization of SGLT2 inhibitors is not significantly linked to an elevated risk of fractures in individuals with T2DM. However, further clinical investigations and extended follow-up periods are warranted to establish more conclusive determinations.